Review Article

COVID-19 An update on oral symptoms, newer variants, second wave and vaccination drive in India — A Review

Srilekha Jayakumar1,*, Chakravarthy Srinivas Vineetha1, Bindu Meera John1, Karthikeyan Arumugam1, Dinesh Sridhar1

1Dept. of Conservative Dentistry and Endodontics, Sri Venkateshwaraa Group of Institutions. Sri Venkateshwaraa Dental College and Hospital, Ariyur, Puducherry, India

A R T I C L E   I N F O

Article history:
Received 01-07-2021
Accepted 06-08-2021
Available online 24-09-2021

Keywords:
Corona virus
Covid Tongue
Dyguesia
Vaccines

A B S T R A C T

A serious threat to world now is the emergence of COVID-19 (Corona Virus Diseases-2019). When compared to its precursor virus, SARS (Severe acute respiratory syndrome – now called as SARS-CoV-1) and MERS (Middle East respiratory syndrome), this virus spreads more rapidly. The emergence of this virus happened in december 2019 in Wuhan. World Health Organisation announced this virus outbreak as a pandemic on March 20th, 2020. The current threat to the world is the emergence of second wave of COVID -19 that has shaken many countries in world and its peak in India was in the month of may 2021 which had drastically affected the country. Hence this review gives a comprehensive update on corona virus and its newer oral symptoms and about treatment approaches and vaccines currently available in India.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

The disease caused by corona virus has been termed as COVID-19 (Corona Virus disease -2019) and is a new virus that has not been previously identified in humans.1 Following the first wave, due to its rapid spread and numerous mutant strains that are developing, the second wave has totally wobbled many countries in the world and India had faced tragedy of second wave were the single day spike of COVID -19 case was above 3.5 – 4 lakhs. There has been a change in pattern of signs and symptoms and a variation in range of the affected age groups due to the development of newer strains of the virus. Apart from restrictions of gatherings and personal protective aids, researchers are now focussing on mass immunisation programs by vaccination.2,3

1.1. Mechanism of corona virus entry into human cell

Corona viruses are spherical enveloped particles containing single-stranded RNA with a nucleoprotein present within a capsid consisting of matrix protein. The envelope has club-shaped glycoprotein surface projections.4 The genome of corona virus encodes five structural proteins such as, Spike protein, Membrane protein, Nucleocapsid protein, Hemagglutinin esterase (HE), and Small envelope protein.5,6 Several mutations have been occurring in corona virus especially in its spike protein, that has resulted in numerous variants arousal in different parts of the world (Table 1, 2). Now a striking threat to the world is arousal of “Delta plus” variant.7,8

The entry of corona virus in the host cell is mediated by spike proteins. Corona viruses mostly recognize aminopeptidases or carbohydrates as an important receptor for entering into human cells. The spike protein contains a 3-dimensional structure in the receptor binding region to maintain the van der Waals forces. The 394 glutamine
residues in the receptor binding region of SARS-CoV-2 is recognized by the lysine 31 residue on the human angiotensin converting enzyme receptor (ACE 2). This interaction between the virus and ACE receptor on human cell facilitate the virus to enter into the host cell.\textsuperscript{9}

1.2. The outbreak and symptoms of COVID-19

The outbreak of novel corona virus and second wave hit is rapidly alarmed the world and resulted in a global health emergency. India experienced massive second wave of COVID-19 which was threatening the entire nation. This disease mainly affects the lung’s efficiency to exchange oxygen and resulting in difficulty to breathe. Patients infected with SARS-CoV-2 have mainly shown pneumonia like symptoms that include fever, cough, shortness of breath, sputum production and myalgia or fatigue, indicating that corona virus affects the respiratory tract and causes acute respiratory disease. Apart from the respiratory symptoms, patients have developed other symptoms which appears within 2 to 14 days after exposure to the virus.\textsuperscript{10,11}

1. Gastrointestinal\textsuperscript{10,11} — Diarrhea, poor appetite, nausea, vomiting
2. Central nervous system\textsuperscript{10,11} — Headache and confusion
3. Cardio vascular system\textsuperscript{10,11} — Palmus, chest distress
4. Other symptoms\textsuperscript{10,11} — Loss of smell and taste
5. Oral Symptoms — loss of taste and COVID tongue (Table 3)

1.3. Preventive measures and treatment modalities in India

Routes of transmission of corona virus includes, Direct transmission (through cough, sneeze, or droplet inhalation), Contact transmission (through oro-nasal-ocular route) and Aerosol transmission. Following the outbreak of second wave Centers for Disease Control and Prevention (CDC) has updated its guidelines for the use of masks.\textsuperscript{12}

1. Doubling your mask\textsuperscript{12,13} — wearing a cloth mask over a surgical mask provides more protection.
2. Knotting the ear loops\textsuperscript{12,13} — Knotting the ends of the ear loops is another way to ensure that the mask covers your mouth and nose completely and thus reducing the exposure by more than 95 per cent
3. Using mask fitter\textsuperscript{12,13} — to improve the fitting of the mask, use a mask fitter or nylon covering over the mask is recommended and this will also prevent from inhaling the aerosol particles.
4. CDC does not recommend the use of N95 respirators for protection against COVID-19 in non-healthcare settings. N95 (filter up to 95% of particles in the air) respirators should be prioritized for healthcare personnel.\textsuperscript{12,13}

2. Vaccination Drive in India

Government of India ensure to take all necessary steps to face the challenge and threat posed by COVID-19. At present, the priority of the government is to make COVID-19 vaccine available to all. COVID-19 vaccination drive has been initiated to cover healthcare and frontline workers from January 16\textsuperscript{th} 2021, for citizens — above 60 years of age from March 1\textsuperscript{st} 2021, above 45 years of age from April 1\textsuperscript{st} 2021, above 18 years of age from May 1\textsuperscript{st} 2021.

Co-WIN application is the digital platform for the vaccination drive in India. The CO-WIN application will help the citizen with an option to register and schedule the vaccination session online in centers of their choice. Covishield and Covaxin received first Emergency use Authorisation by National Regulator on January 16\textsuperscript{th} 2021. Vaccination drive to be expanded with Sputnik V, Pfizer and Moderna in India in upcoming days.\textsuperscript{21}

2.1. Covaxin (BBV152)\textsuperscript{22,23}

2.1.1. Development

By Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) — National Institute of Virology (NIV).

2.1.2. Technology

Inactivated vaccine developed using Whole-Virion Inactivated Vero Cell. Advantage of inactivated vaccines is that they do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to trigger the immune response. Covaxin is able to induce both Th1 T-cell responses and humoral response in the host.

2.1.3. Special features

COVAXIN has immune-potentiators, also known as vaccine adjuvants — Algel — IMDG (Chemosorbed imidazoquinoline onto the aluminium hydroxide gel) that boost immunogenicity.

2.1.4. Dosage

Vaccine given in two doses, 4 to 6 weeks apart (28 to 48 days)

2.1.5. Storage temperature

2 to 8 degree Celcius.

2.1.6. Efficacy

Covaxin demonstrated efficacy of 81 percent in Phase 3 clinical trials. Effective against united kingdom, Brazil and Indian variants of corona virus.
**Table 1:** Corona virus variants reported in the different parts of the world

| S.no | Corona virus variants | First reported country               |
|------|-----------------------|--------------------------------------|
| 1.   | B.1.1.7 (Alpha)       | United Kingdom, UK variant            |
| 2.   | P.1 (Gamma)           | Japan and Brazil                      |
| 3.   | P.2                   | Brazil                                |
| 4.   | B.1.351 (Beta)        | South Africa                          |
| 5.   | B.1.427               | United States (California)            |
| 6.   | B.1.429               | United States-(California)            |
| 7.   | B.1.1.7 + B.1.429 (US-UK variant) | United States-(California)          |
| 8.   | B.1.525               | United kingdom                        |
| 9.   | B.1.617               | India (double mutant)                 |
| 10.  | B.1.617.2 (Delta), B.1.617.2.1 | Delta variant - India, Delta plus variant - Europe |

**Table 2:** Significant key features of corona virus variants

| S.no | Variants | Features |
|------|----------|----------|
| 1    | B.1.1.7 B.1.427 B.1.1.7 + B.1.429 (US-UK variant) | Increased transmissibility rate |
| 2    | P.1 B.1.351 B.1.427 B.1.429 | Decrease in susceptibility to the combination of bamlanivimab and etesevimab monoclonal antibody treatment. |
| 3    | P.2       | Escape the antibodies for other variants |
| 4    | B.1.617 B.1.525 | Evade host immune responses |
| 5    | B.1.1.7 + B.1.429 (US-UK variant) B.1.429 | Escape antibodies which is produced post vaccination. |
| 6    | B.1.617.2 | 40-60% more contagious or transmissible than the Alpha variant (U.K./B.1.1.7) |
| 7    | B.1.617.2.1 | Evading immunity that people developed from vaccination well as natural immunity after recovering from COVID |

**Table 3:** Oral manifestations of COVID-19

| Oral manifestations | Pathophysiology |
|---------------------|-----------------|
| Loss of taste       | ACE2 is expressed in human oral tissues, especially enriched in dorsal tongue. SARS-CoV-2 would cause direct damage to ACE2-expressing cells of taste buds during the cellular entering process, resulting in gustatory dysfunction. Patients presented a prevalence of 45% for taste disorders, 38% for dysgeusia, 35% for hypogeusia, and 24% for ageusia. Zinc deficiency is considered as one of causative factors for gustatory dysfunction associated with COVID-19. A decreased zinc level favours the interaction of zinc-dependent metalloenzyme ACE2 with spike proteins of SARS-CoV-2 but an increased zinc level inhibits ACE2 expression. Hyposalivation – reduced secretion of saliva | Human salivary glands express ACE2 and TMPRSS2, salivary gland infection with SARS-CoV-2 affects saliva secretion, thereby disrupting the taste sensation. SARS-CoV-2 could cause acute sialadenitis by binding to ACE2 receptors in the epithelia of salivary glands, resulting cell lysis. Zinc deficiency also an added factor for sialadenitis The SARS-CoV-2 enters the peripheral nervous system (supplying the salivary gland) and damage it during their neuroinvasion, affecting the function of salivary glands. Viral invasion by trans-synaptic pathway. |
| Sialadenitis and Xerostomia | SARS-CoV-2 could cause acute sialadenitis by binding to ACE2 receptors in the epithelia of salivary glands, resulting cell lysis. Zinc deficiency also an added factor for sialadenitis The SARS-CoV-2 enters the peripheral nervous system (supplying the salivary gland) and damage it during their neuroinvasion, affecting the function of salivary glands. Viral invasion by trans-synaptic pathway. | |
| Mucosal lesions      | Reports shows COVID-19 patients developed ulcers on hard palate, tongue and buccal mucosa, erosions of lips and buccal mucosa. The most common site of lesions is tongue (38%), followed by labial mucosa (26%) and palate (22%). Hyper-inflammatory response secondary to the viral infection are linked to oral mucosal lesions associated with COVID-19. Expression of higher inflammatory cytokines IL-6 may contribute to mucosal lesions. | |
| COVID tongue         | Presents with irregular areas of depapillation on the dorsal surface of the tongue. Few literatures shows evidence suggesting that Geographic tongue might be associated with elevated levels of the inflammatory cytokine interleukin-6 (IL-6). This is the cytokine that is upregulated in severe COVID-19 disease. | |
| Periodontal Diseases | ACE 2 and furin are expressed in sulcular and periodontal pocket epithelium which aid in viral invasion. Therefore, SARS-CoV-2 infects these epithelial cells resulting in periodontal diseases. Literature shows Prevotella intermedia is frequently detected in COVID-19 patients, SARS-CoV-2 could predispose individuals to a periodontal disease through bacterial co-infection by Prevotella intermedia. | |
2.1.7. **Side effects**
Pain at the injection site, Headache, fatigue and fever. No severe or life-threatening (i.e grade 4 and 5) adverse events were reported.

2.2. **Covishield**
2 to 8 degree celcius

2.2.1. **Development**
developed by Oxford University in collaboration with AstraZeneca and manufactured in India by Pune’s Serum Institute of India.

2.2.2. **Technology**
ChAdOx1 nCoV-19 vaccine (AZD1222) is a chimpanzee adenoviral vectored vaccine with full length SARS-CoV-2 spike insert. A viral vector vaccine uses a harmless version of a different virus, called a “vector,” to deliver information to the body that helps it protect and trigger the immune response.

2.2.3. **Special features**
Vector technology, previously the same technology used for preparation of vaccine for EBOLA virus, other ingredients in covishield are L-Histidine, L-Histidine hydrochloride monohydrate, Magnesium chloride hexahydrate, Polysorbate 80, Ethanol, Sucrose, Sodium chloride, Disodium edetate dihydrate (EDTA) and Water.

2.2.4. **Dosage**
Two doses, 6 to 8 weeks (42 to 56 days).

2.2.5. **Storage temperature**
To 8 degree Celcius

2.2.6. **Efficacy**
Trial shows when doses were given one month apart, efficacy was 60-70 percent. Another trial shows when two doses given 2-3 months apart, efficacy was 90 per cent.

2.2.7. **Side effects**
Pain or tenderness at the injection site, Headache, Tiredness, Muscle or joint aches, Fever, Chills, Nausea, enlarged lymph nodes, excessive sweating, itchy skin or rash.

2.3. **Sputnik V**

2.3.1. **Development**
developed by Gamaleya Research Institute and the Russian defence ministry partnered with Dr Reddy’s in September 2020 to conduct clinical trials of Sputnik V in India.

2.3.2. **Technology**
Two-dose adenoviral vector vaccine using two different adenoviruses for each dose.

2.3.3. **Special feature**
A vector vaccine based on adenovirus DNA (adenovirus serotypes 5 and 26 are used), in which the SARS-CoV-2 coronavirus gene is integrated. Adenovirus is used as a “container” to deliver the coronavirus gene (the antigen insert is an unmodified full-length S-protein) to cells and start the synthesis of the new coronavirus’s envelope proteins triggering the immune system.

2.3.4. **Dosage**
Days to three months

2.3.5. **Storage temperature**
2-8 degree Celcius.

2.3.6. **Efficacy**
Clinical trials reported 91.6% efficacy rate.

2.3.7. **Side effects**
Slight body temperature rise and pain around the injection site.

2.4. **Pfizer (BNT162b2)**

2.4.1. **Development**
By Pfizer and BioNTech

2.4.2. **Technology**
mRNA vaccine, consist of genetic information (spike protein) from the virus in the form of messenger RNA.

2.4.3. **Special feature**
Uses lipid nanoparticles that encase the RNA, protect it and helps it to slide inside the cell. Active ingredients are nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2, lipids, salts and sucrose.

2.4.4. **Dosage**
Two doses, 21 days apart.

2.4.5. **Storage temperature**
Degree celcius

2.4.6. **Efficacy**
Phase 3 trial of the BNT162b2 vaccine showed 95% efficacy
2.4.7. Side effects
Pain at injection-site, headache, fatigue.

3. Drugs Used For COVID-19 in India

3.1. Remdesivir

Remdesivir recommended candidate for the treatment of COVID-19. Remdesivir formerly known as GS-5734, is a monophosphoramidate prodrug of an adenosine analog that was developed in response to the Ebola virus outbreak in West Africa in 2014. Mechanism of action is a viral RNA-dependent RNA polymerase (RdRp) inhibitor, targeting the viral genome replication process thus halting the replication of virus.28,29

Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2 (used to treat moderate to severe active rheumatoid arthritis) is now recommended for COVID-19 treatment because of its inhibitory effect on SARS-CoV-2 endocytosis and on the intracellular signaling pathway of cytokines that is responsible for the hyperinflammatory state that results in severe illness. Remdesivir in combination with baricitinib has been granted a Emergency Use Authorization by the FDA for clinical use in adult and pediatric patients two years of age or older hospitalized with COVID-19 requiring supplemental oxygen (SpO₂<94%).30,31

3.2. Virafin

Virafin, the antiviral drug by Zydus Cadila, has received emergency use authorization by the Drugs Controller General of India (DCGI) for treatment of moderate cases of COVID-19. It was originally used for treating Hepatitis C virus infection. Virafin is Pegylated Interferon alpha -2b can thus preventing severe respiratory distress and failure.32-34

4. Conclusion

Coronavirus has massively struck the entire world and various clinical studies has reported arousal of newer symptoms, of which oral symptoms also plays important role in identification of the diseases. Dentist should take the responsibility to screen and identify the oral symptoms of COVID-19, that is likely occur as co-infection or secondary manifestation of COVID-19. India is now in serious thrive to come out of this second wave of COVID-19. Health care professionals are working hard to bring back the nation to a normal pace. Government of India is taking necessary steps to vaccinate each and every citizen of India.

5. Source of Funding

None.

6. Conflict of Interest

None.

References

1. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12:9. doi:10.1038/S41368-020-0075-9

2. For Information on COVID-19 Vaccine; 2021. Available from: https://www.mohfw.gov.in/

3. Website of Ministry of Health and Family Welfare; 2019. Available from: https://www.india.gov.in/ministry-health-and-family-welfare-6

4. Wu A, Peng Y, Huang B. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020;27(3):325–8. doi:10.1016/j.chom.2020.02.018

5. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):127–47.

6. Lu R, Zhao X, Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. doi:10.1016/S0140-6736(20)30476-6

7. SARS-CoV-2 Variant Classifications and Definitions; 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html.

8. Pedrosa MDS, Sipert CR, Nogueira FN. Altered taste in patients with COVID-19: the potential role of salivary glands. Oral Dis. 2021;27(3):798–809. doi:10.1111/odis.13596

9. Xu X, Chen P, Wang J. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457–60. doi:10.1007/s11427-020-1637-5

10. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;6736(20):30211–8. doi:10.1016/S0140-6736(20)30477-1

11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5

12. Your Guide to Masks; 2019. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/about-face-coverings.html.

13. Brooks JT, Beezhold D, Noti JD. Maximizing fit for cloth and medical procedure masks to improve performance and reduce SARS-CoV-2 transmission and exposure. 2021. MMWR Morb Mortal Wkly Rep. 2021;70(7):254–7.

14. Vaira LA, Salzano G, Petrocelli M, Deiana G, Salzano FA, Riu D. Validation of a self-administered olfactory and gustatory test for the remote evaluation of COVID-19 patients in home quarantine. Head Neck. 2020;42(7):1570–6. doi:10.1002/hed.26255

15. Pellegrino R, Cooper KW, Pizzo D, Joseph A, Bhutani S. Corona viruses and the chemical senses: past, present, and future. Chem Senses. 2020;45(6):415–22. doi:10.1093/chemse/bjaa111

16. Jothimani D, Kailasam E, Danielraj S, Ramani V, Ramachandran R, Sekar P, et al. COVID-19: Poor outcomes in patients with zinc deficiency. Int J Infect Dis. 2020;100:343–9. doi:10.1016/j.ijid.2020.03.012

17. Lechien JR, Chetrit A, Idrissi YC, Distinguin L, Circiu M, Saussez S, et al. Parotitis-Like Symptoms Associated with COVID-19. Emerg Infect Dis. 2020;26(9):2270–1. doi:10.3201/eid2609.202059

18. Iranmanesh B, Khalili M, Amiri R, Zartab H, Aflatoonian M. Oral manifestations of COVID-19 disease: A review article. Dermatol Ther. 2021;34(1):14578. doi:10.1111/dth.14578

19. Ansari R, Gheitani M, Heidari F, Heidari F. Oral cavity lesions as a manifestation of the novel virus (COVID-19). Oral Dis. 2021;27:371–
2. Patel J, Woolley J. Necrotizing periodontal disease: Oral manifestation of COVID-19. *Oral Dis*. 2021;27(3):768–9. doi:10.1111/odi.13462.

20. Vaccination; 2021. Available from: https://www.mohfw.gov.in/covid_vaccination/vaccination/index.html.

21. Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. *Lancet Infect Dis*. 2021;7:950–61. doi:10.1016/S1473-3099(21)00009-1.

22. Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2. *J Travel Med*. 2021;28(4):51. doi:10.1093/jtm/taab051.

23. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. *Lancet*. 2021;397(10269):72–4. doi:10.1016/S0140-6736(20)32623-4.

24. Kalil AC, Thomas F, Patterson MD, Anees K, Mehta MD, Kay M, et al. Baricitinib plus Remdesivir for hospitalized adults with COVID-19. *N Engl J Med*. 2021;384:795–807. doi:10.1056/NEJMoa2031994.

25. Kalil AC, Thomas F, Patterson MD, Anees K, Mehta MD, Kay M, et al. Baricitinib plus Remdesivir for hospitalized adults with COVID-19. *N Engl J Med*. 2021;384:795–807. doi:10.1056/NEJMoa2031994.

26. Kalil AC, Thomas F, Patterson MD, Anees K, Mehta MD, Kay M, et al. Baricitinib plus Remdesivir for hospitalized adults with COVID-19. *N Engl J Med*. 2021;384:795–807. doi:10.1056/NEJMoa2031994.

27. Skowronski DM, Serres D. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2021;383(16):2603–2615. doi:10.1056/NEJMoa2034577.

28. Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and Other Viral Diseases. *Clin Microbiol Rev*. 2020;34(1):162–82. doi:10.1128/CMR.00162-20.

29. Al-Abdouh A, Bizanti A, Barbarawi M, Jabri A, Kumar A, Fashanu OE, et al. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. *Contemp Clin Trials*. 2021;101:106272. doi:10.1016/j.cct.2021.106272.

30. Kalil AC, Thomas F, Patterson MD, Anees K, Mehta MD, Kay M, et al. Baricitinib plus Remdesivir for hospitalized adults with COVID-19. *N Engl J Med*. 2021;384:795–807. doi:10.1056/NEJMoa2031994.

31. Sodani P, Mucci L, Girolimetti R, Tedesco S, Monaco F, Campanozzi D, et al. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis. *Respir Med Case Rep*. 2020;31:101115. doi:10.1016/j.rmcr.2020.101115.

32. Zydus Cadila Gets DCGI Nod To Moderate Covid-19 Drug Virafin; 2021. Available from: https://medicaldialogues.in/news/industry/pharma/zydus-cadila-gets-dcgi-nod-to-moderate-covid-19-drug-virafin-76909.

33. Hathway R. Covid Tongue. *Br Dent J*. 2021;230(3):114. doi:10.1038/s41415-021-2666-z.

34. Riad A, Kassem I, Hockova B, Badrah M, Klugar M. Halitosis in COVID-19 patients. *Spec Care Dent*. 2021;41(2):282–5. doi:10.1111/scd.12547.

Author biography

Srilekha Jayakumar, Assistant Professor
https://orcid.org/0000-0002-0548-6631

Chakravarthy Srinivas Vineetha, Assistant Professor

Bindu Meera John, Associate Professor
https://orcid.org/0000-0002-5430-9252

Karthikeyan Arumugam, Assistant Professor

Dinesh Sridhar, Professor and HOD
https://orcid.org/0000-0001-8583-1062

Cite this article: Jayakumar S, Srinivas Vineetha C, Meera John B, Arumugam K, Sridhar D. COVID-19 An update on oral symptoms, newer variants, second wave and vaccination drive in India — A Review. *Int J Oral Health Dent*. 2021;7(3):155-160.